SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
| PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Date of Report (Date of Earliest Event Reported): April 1, 2004
AVANIR PHARMACEUTICALS
| California | 001-15803 | 33-0314804 | ||
| (State of Incorporation or Organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 11388 Sorrento Valley Road, Suite 200, San Diego, California | 92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 622-5200
| NOT APPLICABLE | ||
| (Former Name or Former Address, if Changed Since Last Report) |
| Item 5. Other Events | ||||||||
| Item 7. Exhibits | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 3.1 | ||||||||
Item 5. Other Events.
On April 1, 2004, Avanir Pharmaceuticals amended and restated its Articles of Incorporation for the purposes of restating certain earlier amendments, eliminating certain classes and series of stock no longer outstanding, and giving effect to an increase in the authorized number of shares of Class A common stock, all of which were approved at the Annual Meeting of Shareholders held on March 18, 2004. The Amended and Restated Articles of Incorporation have been filed herewith as Exhibit 4.1 and are incorporated herein by reference.
Item 7. Exhibits.
The following exhibits are furnished with this report.
| Exhibit No. |
Description |
|
3.1
|
Amended and Restated Articles of Incorporation |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: April 5, 2004
| AVANIR PHARMACEUTICALS | ||||
| By: | /s/ Gregory P. Hanson | |||
| Gregory P. Hanson | ||||
| Chief Financial Officer | ||||